Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

GLYCOSA Study:Effect of PAP Treatment on Glycemic Control in Patients With Type 2 Diabetes

This study has been completed.
Royal North Shore Hospital
Baker IDI Heart and Diabetes Institute
International Diabetes Center at Park Nicollet
Information provided by (Responsible Party):
ResMed Identifier:
First received: July 29, 2007
Last updated: December 4, 2013
Last verified: December 2013
Results First Received: August 8, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Diabetes Mellitus Type 2
Interventions: Device: Positive Airway Pressure therapy
Behavioral: Lifestyle counseling

  Participant Flow

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
118 subjects (of the 416 that started in the participant flow module) were not included in endpoint analysis due to reanalysis of OSA inclusion criteria. Thus, 298 of the 416 were included for final analysis.

Reporting Groups
Lifestyle Counseling With PAP Therapy No text entered.
Lifestyle Counseling No text entered.
Total Total of all reporting groups

Baseline Measures
    Lifestyle Counseling With PAP Therapy     Lifestyle Counseling     Total  
Number of Participants  
[units: participants]
  151     147     298  
[units: participants]
<=18 years     0     0     0  
Between 18 and 65 years     84     90     174  
>=65 years     67     57     124  
[units: years]
Mean (Standard Deviation)
  62.4  (9.1)     62.1  (9.0)     62.3  (9.0)  
[units: participants]
Female     52     54     106  
Male     99     93     192  
Region of Enrollment  
[units: participants]
United States     54     59     113  
Australia     97     88     185  

  Outcome Measures

1.  Primary:   HbA1c Change   [ Time Frame: Baseline to Month 6 ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information